Histological distributions of all sarcoma patients (Fig. 2c) compared with patients with aberrant CDKN2A (Fig. 2d), showed an increase in the representation of UPS, MPNST, and MFS patients, and a decrease in the amount of LMS and LPS patients in those with CDKN2A loss. Here, CDKN2A is linked to malignant peripheral nerve sheath tumor.